MC LMS - Beyond Blood Glucose....Pharmacologic Options to Further Reduce Risk of Morbidity & Mortality in those with Type 2 Diabetes

Beyond Blood Glucose....Pharmacologic Options to Further Reduce Risk of Morbidity & Mortality in those with Type 2 Diabetes

Speakers:

Dawn Battise, PharmD, BCACP
Jacqueline L. Olin, MS, PharmD, BCPS, CDCES

Objectives:

Interpret key findings from cardiovascular clinical trials with glucagon-like peptide 1 receptor agonists (GLP1 RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i)
Differentiate between new Food and Drug Administration (FDA) approvals for GLP1 RA and SGLT2i
Formulate specific treatment plans for individuals with type 2 diabetes and atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease

Continuing Education:

Correspondence (1 hr)

Distributors may purchase multiple copies of packages to distribute to learners, and follow their progress. Bulk discounts are below.

Quantity	Price per voucher
1+	$0.00

Beyond Blood Glucose....Pharmacologic Options to Further Reduce Risk of Morbidity & Mortality in those with Type 2 Diabetes
Assessment - Beyond Blood Glucose....Pharmacologic Options to Further Reduce Risk of Morbidity & Mortality in those with Type 2 Diabetes